All G Foods, a Sydney-based startup, is making waves in the world of precision fermentation by focusing on producing high-value dairy proteins. Their mission? To create a sustainable and ethical alternative to traditional dairy products without compromising on quality or functionality.
From Pet Care to Precision Fermentation
Founded in 2020 by Jan Pacas, the co-founder of Australia’s largest online pet care marketplace Mad Paws and HR software startup Flare (later acquired by MYOB), All G is backed by a team with a proven track record in building successful businesses. Pacas joined forces with Dr. Jared Raynes, a molecular biologist with a decade of experience in producing phosphorylated beta casein proteins via microbial fermentation at Australia’s national science agency CSIRO.
A Profitable Approach to Cellular Agriculture
Pacas emphasizes All G’s commitment to profitability from the outset. “In cellular agriculture, there’s been too many examples where people are selling with a negative margin, and that’s not us,” he states. “So we’re launching bovine lactoferrin with 99%+ purity as our first product next year, with human lactoferrin later.”
Their strategy involves targeting high-value markets with premium pricing before gradually expanding to lower-margin, higher-volume segments. Casein proteins are their next target, with a focus on achieving the required price points for mainstream applications.
Unlocking the Potential of Lactoferrin
Bovine lactoferrin, an iron-binding anti-microbial protein found in mammalian milk, offers numerous benefits for immunity, iron regulation, digestive health, endurance, and muscle strength. However, its high cost and complex extraction process have limited its widespread use.
All G’s precision fermentation process, using genetically engineered Pichia yeast, promises to unlock new markets for this valuable ingredient. Pacas believes their approach will significantly expand the market for bovine lactoferrin, with applications in adult nutrition, nutraceuticals, and cosmetics.
Regulatory Approvals and Manufacturing Partnerships
All G is actively pursuing regulatory approvals, aiming for self-GRAS status in the US and a ‘no questions’ letter from the FDA next year, and seeking approval in a major Asian market. They are collaborating with contract manufacturing partners such as Liberation Labs in the US and Cauldron in Australia to ensure a robust production pipeline.
Their strategic partnerships also include Döhler for pilot plant operations and distribution, and Woolworths, a major Australian supermarket chain, through its venture arm W23.
Recreating Casein Functionality with Precision
All G’s approach to casein proteins goes beyond simply replicating the protein structure. Dr. Raynes, leveraging his extensive research background, focuses on precisely replicating the post-translational modifications that occur naturally in cow’s milk, ensuring the same functionality and texture desired in dairy products.
Their patented technology allows them to produce stable casein micelles with unique properties, opening doors to customized solutions for food companies seeking to improve their products or develop novel applications.
Investing in the Future of Food
All G has raised around AUD45 million ($30 million) to date from investors including Döhler Ventures, Agronomics, Woolworths’ W23, and Clean Energy Finance Corp. They are currently raising a bridge round ahead of a larger funding round in 2026.
As the alternative protein landscape evolves, All G Foods is positioned to be a leader in providing sustainable and high-quality dairy alternatives. Their commitment to profitability, innovation, and strategic partnerships sets them apart in this rapidly growing market.
Stay tuned for more exciting developments from All G Foods as they continue to revolutionize the future of food.